Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials

Seminars in Oncology

Volumn 28, Issue 1 SUPPL. 2, 2001, Pages 4-9

  Shepherd, Frances A ^a,g   Fossella, Frank V ^a,b,c,d,e,f   Lynch, Thomas ^a,b,c,d,e,f   Armand, Jean Pierre ^a,b,c,d,e,f   Rigas, James R ^a,b,c,d,e,f   Kris, Mark G ^a,b,c,d,e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CISPLATIN; DOCETAXEL; IFOSFAMIDE; MORPHINE; NAVELBINE;

ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; NAUSEA; NEUROTOXICITY; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

EID: 0035084263     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.18389     Document Type: Review

References (19)

1. Cancer statistics, 1999
2. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer
3. Chemotherapy for advanced non-small cell lung cancer
4. Management issues for stage IV non-small cell lung cancer
5. Locally advanced, unresectable non-small cell lung cancer: New treatment strategies
6. Single agent docetaxel in patients with refractory non-small cell lung cancer
7. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
8. A prospective randomized trial of docetaxel (Taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
9. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with a platinum containing agent
10. Multidisciplinary approach to potentially curable non-small cell lung carcinoma of the lung
11. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer
12. Current status and novel therapeutic approaches in advanced non-small cell lung cancer
13. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer
14. Phase II trials of taxotere with non-small cell lung cancer
15. Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer: A confirmation of prolonged survival in a multicenter trial
16. Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC
17. 2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC)
18. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer
19. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer